Prescribing information

 

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

Inclisiran works differently from other LDL-C-lowering therapies by harnessing the intrinsic process of RNAi to increase hepatic LDL-C uptake and reduce LDL-C levels in the bloodstream.1-3 

Watch the video below to learn more about the mechanism of action of inclisiran.

 

Multiple factors explain the sustained duration of effect of inclisiran:

Chemical modifications increase the stability of inclisiran by decreasing its susceptibility to degradation from exonucleases and endonucleases4
Inclisiran is slowly released from the hepatic endosomes into the cytoplasm4
   
Formation of the inclisiran-RISC complex protects inclisiran and enhances its duration of action4
   
A single siRNA(inclisiran)-bound RISC complex can cleave many target protein-coding mRNA transcripts5
 

 

injection icon

Learn more about the inclisiran clinical trial data

 

 

For further information please refer to the Summary of Product Characteristics by clicking here

 

Inclisiran is not yet available to prescribe in the UK.

 

LDL-C, low-density lipoprotein cholesterol; mRNA, messenger ribonucleic acid; RISC, RNA-induced silencing complex; RNAi, ribonucleic acid interference; siRNA, small interfering ribonucleic acid.

References

  1. Leqvio® Summary of Product Characteristics.

  2. Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.

  3. Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.

  4. Khvorova A. N Engl J Med 2017;376(1):4–7. 

  5. Fitzgerald K et al. N Engl J Med 2017;376(1):41–51.

Rate this content: 
No votes yet
UK | April 2021 | 104799
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]